Jame Abraham

10.7k total citations · 2 hit papers
168 papers, 4.1k citations indexed

About

Jame Abraham is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jame Abraham has authored 168 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 40 papers in Cancer Research. Recurrent topics in Jame Abraham's work include HER2/EGFR in Cancer Research (35 papers), Cancer Treatment and Pharmacology (29 papers) and Breast Cancer Treatment Studies (24 papers). Jame Abraham is often cited by papers focused on HER2/EGFR in Cancer Research (35 papers), Cancer Treatment and Pharmacology (29 papers) and Breast Cancer Treatment Studies (24 papers). Jame Abraham collaborates with scholars based in United States, United Kingdom and Belgium. Jame Abraham's co-authors include Tito Fojo, Gerald M. Higa, Megan Kruse, Alberto J. Montero, Sobha Kurian, Susan E. Bates, Siddharth Kunte, Alvin H. Moss, H. Richard Alexander and Bradford J. Wood and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jame Abraham

157 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy forHER2 (ERBB2)–Positive Breast Cancer

2019 235 citations Nathaniel Braman, Prateek Prasanna et al. JAMA Network Open profile →
Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity

2022 184 citations Jame Abraham et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jame Abraham United States	33	2.0k	821	810	700	671	168	4.1k
Susan Dent United States	34	2.1k 1.0×	945 1.2×	546 0.7×	268 0.4×	698 1.0×	138	4.3k
Adedayo A. Onitilo United States	28	1.7k 0.9×	619 0.8×	947 1.2×	533 0.8×	360 0.5×	167	3.7k
R. Swindell United Kingdom	49	2.3k 1.2×	1.8k 2.2×	997 1.2×	1.5k 2.1×	700 1.0×	166	6.1k
Lynne Penberthy United States	21	1.8k 0.9×	942 1.1×	838 1.0×	465 0.7×	279 0.4×	36	5.3k
Amanda L. Blackford United States	48	3.6k 1.9×	1.4k 1.6×	1.3k 1.7×	941 1.3×	607 0.9×	227	7.5k
B. K. Edwards United States	17	2.7k 1.4×	902 1.1×	739 0.9×	507 0.7×	271 0.4×	23	4.9k
Masashi Ando Japan	31	2.0k 1.0×	954 1.2×	774 1.0×	431 0.6×	361 0.5×	206	3.6k
Victor R. Grann United States	37	2.7k 1.4×	759 0.9×	1.0k 1.2×	603 0.9×	218 0.3×	66	5.0k
Sercan Aksoy Türkiye	27	1.7k 0.9×	780 1.0×	430 0.5×	428 0.6×	340 0.5×	284	3.6k
Timothy Perren United Kingdom	42	3.0k 1.5×	902 1.1×	873 1.1×	1.3k 1.9×	452 0.7×	151	6.6k

Countries citing papers authored by Jame Abraham

Since Specialization

Citations

This map shows the geographic impact of Jame Abraham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jame Abraham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jame Abraham more than expected).

Fields of papers citing papers by Jame Abraham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jame Abraham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jame Abraham. The network helps show where Jame Abraham may publish in the future.

Co-authorship network of co-authors of Jame Abraham

This figure shows the co-authorship network connecting the top 25 collaborators of Jame Abraham. A scholar is included among the top collaborators of Jame Abraham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jame Abraham. Jame Abraham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnson, Justin M., Halle C. F. Moore, Megan Kruse, et al.. (2024). Abstract PO2-17-12: Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC. Cancer Research. 84(9_Supplement). PO2–17. 1 indexed citations

Abraham, Jame, et al.. (2024). Current and Novel Treatment Options in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. JCO Oncology Practice. 21(2). 145–154. 1 indexed citations

Khorrami, Mohammadhadi, Nathaniel Braman, Siddharth Kunte, et al.. (2023). Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer. npj Breast Cancer. 9(1). 67–67. 4 indexed citations

Stabellini, Nickolas, Paul G. Pavicic, Pingfu Fu, et al.. (2023). Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 30(1). 82–93. 8 indexed citations

Braman, Nathaniel, Prateek Prasanna, Kaustav Bera, et al.. (2022). Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers. Clinical Cancer Research. 28(20). 4410–4424. 19 indexed citations

Kruse, Megan, Mona Patel, Jeffrey M. McManus, et al.. (2021). Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. JCI Insight. 6(20). 15 indexed citations

Moore, Halle C. F., Jame Abraham, Megan Kruse, et al.. (2021). Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors. Clinical Breast Cancer. 22(2). 143–148. 15 indexed citations

Zhou, Yadi, Yuan Hou, Muzna Hussain, et al.. (2020). Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients. Journal of the American Heart Association. 9(23). e019628–e019628. 57 indexed citations

Abraham, Jame, et al.. (2020). Cancer an Emerging Healthcare Crisis in Kerala. 7. 1 indexed citations

10.

Braman, Nathaniel, Prateek Prasanna, Jon Whitney, et al.. (2019). Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy forHER2 (ERBB2)–Positive Breast Cancer. JAMA Network Open. 2(4). e192561–e192561. 235 indexed citations breakdown →

11.

Golubić, Mladen, Halle C. F. Moore, Kenneth J. Weiss, et al.. (2018). Lifestyle Medicine-Focused Shared Medical Appointments to Improve Risk Factors for Chronic Diseases and Quality of Life in Breast Cancer Survivors. The Journal of Alternative and Complementary Medicine. 25(1). 40–47. 16 indexed citations

12.

Abraham, Jame, Humberto Caldera, Robert E. Coleman, et al.. (2018). Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Research and Treatment. 169(1). 1–7. 9 indexed citations

13.

Tiwari, Shruti, Prasun Mishra, Paola Raska, et al.. (2016). Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Research and Treatment. 158(1). 189–193. 19 indexed citations

14.

Abraham, Jame, André Robidoux, Antoinette R. Tan, et al.. (2015). Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. Breast Cancer Research and Treatment. 152(2). 399–405. 19 indexed citations

15.

Kanate, Abraham S., Michael Craig, Aaron Cumpston, et al.. (2011). Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. Hematology/Oncology and Stem Cell Therapy. 4(4). 149–156. 4 indexed citations

16.

Abraham, Jame, Maureen Edgerly, Richard H. Wilson, et al.. (2009). A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine. Clinical Cancer Research. 15(10). 3574–3582. 93 indexed citations

17.

Higa, Gerald M. & Jame Abraham. (2007). Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy. 7(9). 1183–1192. 101 indexed citations

18.

Guo, Lijie, Jame Abraham, Daniel C. Flynn, et al.. (2007). Individualized survival and treatment response predictions for breast cancers using phospho-EGFR, phospho-ER, phospho-HER2/neu, phospho-IGF-IR/In, phospho-MAPK, and phospho-p70S6K proteins. The International Journal of Biological Markers. 22(1). 1–11. 11 indexed citations

19.

Abraham, Jame, Carmen J. Allegra, & James L. Gulley. (2005). Bethesda Handbook of Clinical Oncology, Second Edition, for PDA: Powered by Skyscape, Inc.. Lippincott Williams & Wilkins eBooks. 2 indexed citations

20.

Abraham, Jame, Susan Bakke, Ann Rutt, et al.. (2002). A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. Cancer. 94(9). 2333–2343. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact